Sorafenib, a multi-kinase inhibitor with anti-VEGFR and RAF family kinase activity (inhibitor of the RAF/MEK/ERK pathway) [211], combined with the EGFR inhibitor Erlotinib in the treatment of advanced CCA, has been disappointing [212]. This evidence concerns the gene MAP2K7 and cholangiocarcinoma.